<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Juravinski Cancer Program - current literature awareness in oncology</title>
	<atom:link href="http://jcponcology.wordpress.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://jcponcology.wordpress.com</link>
	<description>current literature awareness in oncology</description>
	<lastBuildDate>Mon, 28 Jul 2008 15:10:54 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<cloud domain='jcponcology.wordpress.com' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://www.gravatar.com/blavatar/b2db3ab9c57324b3f47b4b05f8af631e?s=96&#038;d=http://s.wordpress.com/i/buttonw-com.png</url>
		<title>Juravinski Cancer Program - current literature awareness in oncology</title>
		<link>http://jcponcology.wordpress.com</link>
	</image>
			<item>
		<title>Treating Relapsed or Refractory B-cell Lymphomas</title>
		<link>http://jcponcology.wordpress.com/2008/07/28/treating-relapsed-or-refractory-b-cell-lymphomas/</link>
		<comments>http://jcponcology.wordpress.com/2008/07/28/treating-relapsed-or-refractory-b-cell-lymphomas/#comments</comments>
		<pubDate>Mon, 28 Jul 2008 15:10:54 +0000</pubDate>
		<dc:creator>jcponcology</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://jcponcology.wordpress.com/?p=311</guid>
		<description><![CDATA[Name of the Trial
Phase I/II Study of Flavopiridol in Patients with Refractory or Recurrent Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma (NCI-07-C-0081). See the protocol summary at http://cancer.gov/clinicaltrials/NCI-07-C-0081.
Principal Investigator
Dr. Kieron Dunleavy, NCI Center for Cancer Research
Why This Trial Is Important
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=jcponcology.wordpress.com&blog=1390007&post=311&subd=jcponcology&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://jcponcology.wordpress.com/2008/07/28/treating-relapsed-or-refractory-b-cell-lymphomas/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/63ece1ad611e04fc8e69033aae610171?s=96&#38;d=identicon" medium="image">
			<media:title type="html">jcponcology</media:title>
		</media:content>
	</item>
		<item>
		<title>New Drugs for Multiple Myeloma Consolidation Therapy</title>
		<link>http://jcponcology.wordpress.com/2008/07/10/new-drugs-for-multiple-myeloma-consolidation-therapy/</link>
		<comments>http://jcponcology.wordpress.com/2008/07/10/new-drugs-for-multiple-myeloma-consolidation-therapy/#comments</comments>
		<pubDate>Thu, 10 Jul 2008 14:28:35 +0000</pubDate>
		<dc:creator>jcponcology</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://jcponcology.wordpress.com/?p=305</guid>
		<description><![CDATA[Name of the Trial
Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone with Versus without Lenalidomide in Patients with Symptomatic Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen (ECOG-E1A05). See the protocol summary at http://cancer.gov/clinicaltrials/ECOG-E1A05.
Principal Investigator
Dr. Rafael Fonseca and Dr. S. Vincent Rajkumar, Eastern Cooperative Oncology Group
Why This Trial Is Important
Multiple myeloma [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=jcponcology.wordpress.com&blog=1390007&post=305&subd=jcponcology&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://jcponcology.wordpress.com/2008/07/10/new-drugs-for-multiple-myeloma-consolidation-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/63ece1ad611e04fc8e69033aae610171?s=96&#38;d=identicon" medium="image">
			<media:title type="html">jcponcology</media:title>
		</media:content>

		<media:content url="http://jcponcology.wordpress.com/images/spacer.gif" medium="image" />
	</item>
		<item>
		<title>Treatment for Advanced Carcinoid Tumors</title>
		<link>http://jcponcology.wordpress.com/2008/06/25/treatment-for-advanced-carcinoid-tumors/</link>
		<comments>http://jcponcology.wordpress.com/2008/06/25/treatment-for-advanced-carcinoid-tumors/#comments</comments>
		<pubDate>Wed, 25 Jun 2008 13:14:52 +0000</pubDate>
		<dc:creator>jcponcology</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://jcponcology.wordpress.com/?p=298</guid>
		<description><![CDATA[Name of the Trial
Phase III Randomized Study of Depot Octreotide Acetate and Interferon alfa-2b versus Depot Octreotide Acetate and Bevacizumab in Patients with Unresectable Metastatic or Locally Advanced, High-Risk Neuroendocrine Carcinoid Tumor (SWOG-S0518). See the protocol summary at http://cancer.gov/clinicaltrials/SWOG-S0518.
Principal Investigator
Dr. James Yao, Southwest
Oncology Group
Why This Trial Is Important
Carcinoid tumors originate most often in neuroendocrine cells [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=jcponcology.wordpress.com&blog=1390007&post=298&subd=jcponcology&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://jcponcology.wordpress.com/2008/06/25/treatment-for-advanced-carcinoid-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/63ece1ad611e04fc8e69033aae610171?s=96&#38;d=identicon" medium="image">
			<media:title type="html">jcponcology</media:title>
		</media:content>

		<media:content url="http://jcponcology.wordpress.com/images/spacer.gif" medium="image" />
	</item>
		<item>
		<title>Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer</title>
		<link>http://jcponcology.wordpress.com/2008/06/11/defining-therapy-for-recurrent-platinum-sensitive-ovarian-cancer/</link>
		<comments>http://jcponcology.wordpress.com/2008/06/11/defining-therapy-for-recurrent-platinum-sensitive-ovarian-cancer/#comments</comments>
		<pubDate>Wed, 11 Jun 2008 19:19:04 +0000</pubDate>
		<dc:creator>jcponcology</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://jcponcology.wordpress.com/?p=296</guid>
		<description><![CDATA[Name of the Trial
Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel with Versus without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (GOG-0213). See the protocol summary at http://cancer.gov/clinicaltrials/GOG-0213.
Principal Investigators
Dr. Robert Coleman, Dr. Scott Eisenkop, Dr. Deborah Armstrong, Dr. [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=jcponcology.wordpress.com&blog=1390007&post=296&subd=jcponcology&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://jcponcology.wordpress.com/2008/06/11/defining-therapy-for-recurrent-platinum-sensitive-ovarian-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/63ece1ad611e04fc8e69033aae610171?s=96&#38;d=identicon" medium="image">
			<media:title type="html">jcponcology</media:title>
		</media:content>
	</item>
		<item>
		<title>Selenium to Prevent Recurrence of Colorectal Polyps</title>
		<link>http://jcponcology.wordpress.com/2008/05/29/selenium-to-prevent-recurrence-of-colorectal-polyps/</link>
		<comments>http://jcponcology.wordpress.com/2008/05/29/selenium-to-prevent-recurrence-of-colorectal-polyps/#comments</comments>
		<pubDate>Thu, 29 May 2008 15:28:53 +0000</pubDate>
		<dc:creator>jcponcology</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://jcponcology.wordpress.com/?p=294</guid>
		<description><![CDATA[Name of the Trial
Phase III Randomized Study of Selenium in Patients with Adenomatous Colorectal Polyps (UARIZ-00-0430-01). See the protocol summary at http://www.cancer.gov/clinicaltrials/UARIZ-00-0430-01.
Principal Investigator
Dr. M. Peter Lance, Arizona Cancer Center at University of Arizona Health Sciences Center
Why This Trial Is Important
The mineral selenium, found naturally in grains, meat, and other common foods, is being studied to [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=jcponcology.wordpress.com&blog=1390007&post=294&subd=jcponcology&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://jcponcology.wordpress.com/2008/05/29/selenium-to-prevent-recurrence-of-colorectal-polyps/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/63ece1ad611e04fc8e69033aae610171?s=96&#38;d=identicon" medium="image">
			<media:title type="html">jcponcology</media:title>
		</media:content>
	</item>
	</channel>
</rss>